Condition
Acute Radiation Syndrome
Total Trials
5
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
2 of 4 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
5Total
P 1 (5)
Trial Status
Completed4
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04650555Phase 1CompletedPrimary
BIO 300 Oral Powder Safety and Pharmacokinetics
NCT03585803Phase 1CompletedPrimary
A Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of KMRC011
NCT00903929Phase 1Completed
Phase I Study of Eltrombopag for Promoting Thrombopoiesis After Total Body Irradiation
NCT02587442Phase 1UnknownPrimary
A Study to Evaluate the Safety and Pharmacokinetics of RadProtect® in Healthy Volunteers
NCT00504335Phase 1CompletedPrimary
Safety and Pharmacokinetic Study of BIO 300 Capsules
Showing all 5 trials